0HD2 Stock Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Alnylam Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$147.00 |
| 52 Week High | US$217.98 |
| 52 Week Low | US$143.66 |
| Beta | 0.40 |
| 1 Month Change | 0.65% |
| 3 Month Change | -22.52% |
| 1 Year Change | -27.52% |
| 3 Year Change | 6.70% |
| 5 Year Change | 70.98% |
| Change since IPO | 9.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HD2 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.3% | -1.9% | -0.9% |
| 1Y | -27.5% | -30.5% | -1.8% |
Return vs Industry: 0HD2 exceeded the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0HD2 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0HD2 volatility | |
|---|---|
| 0HD2 Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HD2's share price has been volatile over the past 3 months.
Volatility Over Time: 0HD2's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,100 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.
Alnylam Pharmaceuticals, Inc. Fundamentals Summary
| 0HD2 fundamental statistics | |
|---|---|
| Market cap | US$18.44b |
| Earnings (TTM) | -US$440.24m |
| Revenue (TTM) | US$1.83b |
10.1x
P/S Ratio-41.9x
P/E RatioIs 0HD2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HD2 income statement (TTM) | |
|---|---|
| Revenue | US$1.83b |
| Cost of Revenue | US$310.41m |
| Gross Profit | US$1.52b |
| Other Expenses | US$1.96b |
| Earnings | -US$440.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -3.48 |
| Gross Margin | 83.02% |
| Net Profit Margin | -24.08% |
| Debt/Equity Ratio | -1,086.8% |
How did 0HD2 perform over the long term?
See historical performance and comparison